Company: INMB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001213900-25-073077
Chunk: 90

Company: Inmune Bio, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 2
Chunk 90
---
im Chief Financial Officer, Mr. Ellspermann will continue to serve pursuant to his employment agreement with the Company dated
December 16, 2021, which provides for at-will employment and sets forth his compensation and benefits. Under the employment agreement,
Mr. Ellspermann receives an annual base salary of $181,125 and is eligible for a performance-based bonus, subject to criteria established
by the Company’s compensation committee.

If the Company terminates
Mr. Ellspermann’s employment without Cause (as defined in the employment agreement), he is entitled to nine months of severance
pay, subject to the execution and non-revocation of a release of claims. In the event of a termination without Cause in connection with
a Change in Control (as defined in the employment agreement), all of Mr. Ellspermann’s time-based equity awards will vest in full,
and any options will become fully exercisable.

The employment agreement contains
customary provisions regarding confidentiality, ownership of intellectual property, and restrictions on competition, solicitation, and
interference with the Company’s business relationships during his employment and for one year thereafter.

There are no arrangements
or understandings between Mr. Ellspermann and any other persons pursuant to which he was elected as an officer. Mr. Ellspermann does not
have any family relationships with any of the Company’s directors or executive officers. There are no transactions involving the
Company and Mr. Ellspermann that the Company would be required to report pursuant to Item 404(a) of Regulation S-K.

The terms of employment of
Mr. Ellspermann as the Company’s Interim Chief Financial Officer will be revisited by the Compensation Committee and the Board and
disclosed to the market in the future. The foregoing summary of Mr. Ellspermann’s employment agreement is qualified in its entirety
by reference to the full text of the employment agreement, which is filed as Exhibit 10.5 hereto and incorporated herein by reference.

38

Item 6. Exhibits 

    No.
     
    Description 

    10.1
     
    Second Amended and Restated INmune Bio Inc. 2021 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 10, 2025)  

    10.2
     
    Form of Securities Purchase Agreement,